Skip to main content
SpringerLink
Log in

Kardiovaskuläre Sicherheit von Sitagliptin – die TECOS-Studie sorgt für Klarheit

Cardiovascular Safety of Sitagliptin – TECOS-Study provides assurance

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL (2015) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130(18):1579–1588

    Article  Google Scholar 

  2. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, van de Werf F, Peterson ED, Holman RR, TECOS Study Group (2015) Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373:232–242

    Article  CAS  PubMed  Google Scholar 

  3. White WB, Cannon CP, Heller S, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CP, Kupfer S, Wilson C, Cushman WC, Zannad F, Investigators EXAMINE (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:13227–13235

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knappschaftskrankenhaus Recklinghausen, Klinikum Vest GmbH, Dorstener Str.151, 45657, Recklinghausen, Deutschland

    I. Vardarli EU M.Sc. &  C. Özcelik

Authors
  1. I. Vardarli EU M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Özcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Vardarli EU M.Sc..

Ethics declarations

Interessenkonflikt

I. Vardarli, C. Özcelik geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vardarli, I., Özcelik, C. Kardiovaskuläre Sicherheit von Sitagliptin – die TECOS-Studie sorgt für Klarheit. Kardiologe 9, 334–336 (2015). https://doi.org/10.1007/s12181-015-0020-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-015-0020-x

Search

Navigation